A Pilot Clinical Study of Apatinib Plus Irinotecan in Patients with Recurrent High-grade Glioma: Clinical Trial/Experimental Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Dec 17

PMID 29245310

Citations 29

Authors

Lei Wang

Lijun Liang

Tao Yang

Yun Qiao

Youyou Xia

Liang Liu

Chao Li

Peizhi Lu

Xiaodong Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets. This study was conducted to evaluate the efficacy and safety of apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeted vascular endothelial growth factor receptor 2, combined with irinotecan, in patients with recurrent malignant glioma.

Methods: Ten patients with recurrent malignant glioma who were experiencing relapse after treatment of temozolomide were enrolled in this study. They received oral apatinib (500 mg qd) in conjunction with irinotecan (340 mg/m or 125 mg/m depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles. After that the patients continued to take apatinib as maintenance. Dosage adjustment occurred in only 3 (30.0%) patients.

Results: Among the 10 patients, 9 were available for the efficacy evaluation. There were 5 with partial response, 2 with stable disease and 2 with progressive disease. The objective response rate and the disease control rate (DCR) were 55% (5/9) and 78% (7/9), respectively. The median progress free survival time was 8.3 months. As for safety analysis, the most 3 common adverse events were gastrointestinal reaction (31.8%), hypertension (22.7%), and myelosuppression (18.0%).

Conclusion: Apatinib combined with irinotecan seems to be a promising therapeutic option for recurrent malignant glioma patients. Perspective clinical studies with adequate sample size are required to validate our results.

Trial Registration: NCT02848794 /Ahead-BG306.

Citing Articles

Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advances.

Jia Y, Liu Y, Yang H, Yao F MedComm (2020). 2024; 5(9):e734.

PMID: 39263605 PMC: 11387731. DOI: 10.1002/mco2.734.

Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.

Kuang R, Wang J, Wang Y, Tang X Clinics (Sao Paulo). 2024; 79:100376.

PMID: 38733690 PMC: 11103373. DOI: 10.1016/j.clinsp.2024.100376.

Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).

Yashin K, Yuzhakova D, Sachkova D, Kukhnina L, Kharitonova T, Zolotova A Sovrem Tekhnologii Med. 2024; 15(3):61-71.

PMID: 38435477 PMC: 10904359. DOI: 10.17691/stm2023.15.3.07.

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma.

Lin H, Zhou X, Sheng X, Liang X Drugs R D. 2023; 23(3):239-244.

PMID: 37466833 PMC: 10439071. DOI: 10.1007/s40268-023-00429-3.

Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.

Muzyka L, Goff N, Choudhary N, Koltz M Int J Mol Sci. 2023; 24(13).

PMID: 37445633 PMC: 10341773. DOI: 10.3390/ijms241310456.

References

Cloughesy T, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H . Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003; 97(9 Suppl):2381-6. DOI: 10.1002/cncr.11306. View

Zhang H . Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015; 9:6075-81. PMC: 4654530. DOI: 10.2147/DDDT.S97235. View

Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G . Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol. 2003; 14(4):603-14. DOI: 10.1093/annonc/mdg159. View

Phillips H, Armani M, Stavrou D, Ferrara N, Westphal M . Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. Int J Oncol. 2011; 2(6):913-9. DOI: 10.3892/ijo.2.6.913. View

Lamszus K, Ulbricht U, Matschke J, Brockmann M, Fillbrandt R, Westphal M . Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003; 9(4):1399-405. View

Majmundar A, Wong W, Simon M . Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010; 40(2):294-309. PMC: 3143508. DOI: 10.1016/j.molcel.2010.09.022. View

Nieder C, Grosu A, Molls M . A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2001; 26(6):397-409. DOI: 10.1053/ctrv.2000.0191. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

10.

Johansson M, Brannstrom T, Bergenheim A, Henriksson R . Spatial expression of VEGF-A in human glioma. J Neurooncol. 2002; 59(1):1-6. DOI: 10.1023/a:1016317407043. View

11.

Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu L . Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016; 7(13):17220-9. PMC: 4941382. DOI: 10.18632/oncotarget.7948. View

12.

Cohen M, Shen Y, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11):1131-8. DOI: 10.1634/theoncologist.2009-0121. View

13.

Jain H, Nor J, Jackson T . Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral agiogenesis. Bull Math Biol. 2007; 70(1):89-117. DOI: 10.1007/s11538-007-9242-9. View

14.

Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I . Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003; 63(20):6613-25. View

15.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

16.

Friedman H, Petros W, Friedman A, Schaaf L, Kerby T, Lawyer J . Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17(5):1516-25. DOI: 10.1200/JCO.1999.17.5.1516. View

17.

Tong X, Wang F, Liang S, Zhang X, He J, Chen X . Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012; 83(5):586-97. DOI: 10.1016/j.bcp.2011.12.007. View

18.

Prados M, Lamborn K, Yung W, Jaeckle K, Robins H, Mehta M . A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006; 8(2):189-93. PMC: 1871932. DOI: 10.1215/15228517-2005-010. View

19.

Brem S, Bierman P, Black P, Blumenthal D, Brem H, Chamberlain M . Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005; 3(5):644-90. DOI: 10.6004/jnccn.2005.0038. View

20.

Huncharek M, Muscat J . Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 1998; 18(2B):1303-11. View